Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Australian prostate cancer technology company Minomic International Ltd ... ,outstanding, science that uses its patented antibody. ... prostate cancer diagnostic test known as MiCheck® next year, ... the peer-reviewed Australian Museum Eureka Science Prize for ... prize is awarded for ground breaking research that has ...
(Date:9/2/2015)... , September 2, 2015 ... Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben zu ... vom Rare Genomics Institute. Biovista unterstützt ... Medikamenten für die Behandlung anderer Krankheiten als denen, ... Steven Laffoon und sein Team bei der ...
(Date:9/2/2015)... England (PRWEB) , ... September 02, 2015 , ... ... drug discovery and life science research, today unveiled Genedata Screener ® version ... for all in-vitro screening brings to market a rich set of new capabilities. ...
(Date:9/1/2015)... YORK , Sept. 1, 2015 /PRNewswire-USNewswire/ ... of cancer death in American men. One ... cancer and 233,000 new cases are diagnosed annually. ... experts are using a powerful new technique, ... small and large cancer lesions, treating only the ...
Breaking Biology Technology:Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... in the nanocrystals of semiconductors to cool more slowly ... the potential to improve satellite communications and the generation ... these electronsin this case, by more than 30 timescould ... Guyot-Sionnest, Professor of Chemistry and Physics at the University ...
... Nov. 13 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... &,Company, LLC,s Focus on Infectious Disease Conference on Thursday, ... at the Needham and Company,LLC,s office in New York ... Officer of Anadys,will present an overview of Anadys and ...
... Nov. 13 Franklin & Seidelmann Subspecialty,Radiology ... senior management team,with the appointment of Richard ... In this new position, Dyke will be ... sales activities and new business,development through industry ...
Cached Biology Technology:New research expected to improve laser devices and make photovoltaics more efficient 2Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference 2Franklin & Seidelmann Adds Richard Dyke to Senior Management Team as Senior VP, Sales/Marketing 2
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... This release is available in German . , ... membrane for the absorption of viruses like hepatitis C, herpes, ... germs. However, certain viruses, such as the human immunodeficiency virus ... membrane. Just how this infiltration occurs on a molecular level ...
... fish that sees simultaneously above and below the water line ... allows organisms to adapt to their environment. Gregory L. ... sharp divide between the upper and lower sections of the ... related to guppies. The findings were published today online in ...
... 20, 2011 Whether engaging experts from the outside to ... AIDS, leaders around the globe acknowledge the need to innovate ... facing business and society today. NineSigma, the leading provider of ... the imperative to innovate for organizations is greater than ever, ...
Cached Biology News:Scavenger cells accomplices to viruses 2UBC graduate student discovers key to 'bifocals' in mangrove fish species 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 3NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 4
... Designed for serial ... protein fractions including cytosol/particulate/cytoskeleton/nuclear ... All these fractions can ... downstream assays such as ...
Self Closing Forceps...
... Perfuse cells right in your ... The Petri dish Perfusion Chamber has ... outflow that dampen the fluctuations of ... compartment and prevent bubbles from entering ...
... High Five cells (BTI-TN-5B1-4) derived ... have been shown to be capable ... secreted recombinant proteins compared to other ... the following features:- -Rapid doubling time as ...
Biology Products: